<DOC>
	<DOC>NCT00004420</DOC>
	<brief_summary>OBJECTIVES: I. Determine the efficacy and safety of gammalinolenic acid in the treatment of childhood arthritis.</brief_summary>
	<brief_title>Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, cross over study of 12 months duration. Patients are stratified by type of juvenile rheumatoid arthritis (systemic onset vs pauciarticular disease vs polyarticular disease). Patients are randomized to receive either gammalinolenic acid (GLA) or placebo (safflower seed oil) orally. Parents are asked to maintain the child's usual diet over the course of study. Patients are followed at 3, 6, 9, and 12 months during study and at 6 months thereafter.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Efamol</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Juvenile rheumatoid arthritis (systemic onset, pauciarticular disease, and polyarticular disease) Active synovitis Prior/Concurrent Therapy No more than 2 concurrent nonsteroidal antiinflammatory drugs No more than 2 concurrent second line agents (e.g., Dpenicillamine, oral or injectable gold, antimalarials, methotrexate, sulfasalazine) Must have started second line agent at least 3 months prior to study Must be on stable doses of all medications for at least 1 month prior to study Prior prednisone allowed if started at least 3 months prior to study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>arthritis &amp; connective tissue diseases</keyword>
	<keyword>juvenile rheumatoid arthritis</keyword>
	<keyword>rare disease</keyword>
</DOC>